Ads
related to: atorvastatin normal dosage range
Search results
Results From The WOW.Com Content Network
In a Cochrane systematic review the dose-related magnitude of atorvastatin on blood lipids was determined. Over the dose range of 10 to 80 mg/day total cholesterol was reduced by 27.0% to 37.9%, LDL cholesterol by 37.1% to 51.7% and triglycerides by 18.0% to 28.3%. [101]
Drug interactions are possible, but studies have not shown that these statins increase exposure to ciclosporin. [60] HIV-positive people taking protease inhibitors: Atorvastatin, pravastatin or fluvastatin: Negative interactions are more likely with other choices. [61] Persons taking gemfibrozil, a non-statin lipid-lowering drug Atorvastatin
Statins are linked to better health outcomes in older adults over the age of 70 with or without previous cardiovascular disease, a new study finds.
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]
The therapeutic window (or pharmaceutical window) of a drug is the range of drug dosages which can treat disease effectively without having toxic effects. [18] Medication with a small therapeutic window must be administered with care and control, frequently measuring blood concentration of the drug, to avoid harm.
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia).
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The trial focused on patients with normal low-density lipoprotein (LDL) cholesterol levels but increased levels of high-sensitivity C-reactive protein (hs-CRP). JUPITER was the first clinical trial to indicate that statin therapy may provide benefit to patients with low-to-normal LDL levels and no known cardiovascular disease.